NRx Collaborated with Lotus and Alvogen to Develop and Commercialize NRX-101 for Suicidal Treatment-Resistant Bipolar Depression
- NRx will receive ~$330M in milestones incl. $10M upon P-IIb/III trial & completion of the Type B meeting with the US FDA, $5M upon Alvogen’s receipt of a copy of the US FDA approval for NRX-101, additional milestones fees will be payable upon net sales targets along with royalty on net sales b/w 12% & 16% on sales thresholds in the US & other success-based fees outside of the US
- Lotus to get a global right for NRX-101 & will lead the commercialization of NRX-101 outside the US through Lotus’s direct presence in Asian markets or through its export division in numerous markets, incl. in EU, Japan, China, Australia & Latin America
- Alvogen will lead the US commercialization of NRX-101 & NRx will oversee the clinical development. The agreement incl. a right of 1st negotiation for new indications of NRX-101 & new products containing D-cycloserine + antidepressant/antipsychotic
Ref: Nrxpharma | Image: Alvogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.